FDA rejects Alexza's inhaled psychiatric drug

10/11/2010 | Reuters

Alexza Pharmaceuticals has received a complete-response letter from the FDA for AZ-004, an inhaled treatment for agitation caused by schizophrenia or bipolar disorder. The agency voiced concern about clinical data showing that the drug causes respiratory side effects.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA